Navigation Links
NuView Life Sciences and Thomas Jefferson University Sign Agreement for Exclusive Development and Commercialization Rights to Novel Prostate Cancer Diagnostic
Date:3/26/2013

Park City, UT (PRWEB) March 26, 2013

NuView Life Sciences (NLS), a privately-held company developing next generation imaging and in vitro diagnostic biomarkers with the ability to identify and locate disease at the earliest stages of development, today announced it has entered into an agreement with Thomas Jefferson University for exclusive development and commercialization rights to a novel urine screen for the early detection of Prostate and Bladder Cancer.

“We are excited to add this technology into the NuView Portfolio. This in vitro diagnostic is an excellent complement to our diagnostic imaging biomarkers in development,” stated Brian Dowd, Ph.D., Vice President of Clinical and Scientific Affairs at NLS. “Early and accurate detection of Prostate and Bladder Cancer should result in a significant reduction of invasive biopsy procedures and increase the probability for successful treatment outcomes in patients.”

This novel in vitro diagnostic (IVD) detects minute quantities of cancer cells shed into the urinary tract by measuring the expression of the vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor-1 (VPAC1) receptor. To date, the technology has displayed impressive sensitivity and specificity for the identification of Prostate and Bladder Cancer in human urine samples.

Previous work by Mathew Thakur, Ph.D., academic collaborator, Professor Radiology and Director of Radiopharmaceutical Research and Molecular Imaging at Thomas Jefferson University (TJU), Philadelphia, has shown Prostate Cancer cells express the oncogene product VPAC1 in high density on their cell surface. This occurs at a very early stage in oncogenic transformation, well before cell morphology alterations for histologic confirmation, and even well before the elevation of Prostate Specific Antigen (PSA). NuView is also developing NLS-VPAC1, a positron emission tomography (PET)-based imaging agent that measures VPAC1 expression levels for identification and localization of malignant Breast and Prostate tumors.

There remains a large unmet medical need for the accurate and early detection of Prostate and Bladder Cancer. Prostate cancer is the second leading cause of cancer death in American men and over 72,000 men and women are estimated to be diagnosed with Bladder Cancer in the U.S. in 2013. Mortality from Prostate and Bladder Cancer strongly correlates with the stage of disease upon diagnosis. Therefore, the ability to detect early-stage cancer before clinical presentation would have a dramatic effect upon patient outcomes.

Currently, routine screening of the general public for bladder cancer is not recommended by any major professional organization. This is due to lack of a sensitive and specific test that will detect bladder cancer in individual not presenting clinical symptoms of disease. Current screening for Prostate Cancer by digital rectal examination (DRE) and Prostate Specific Antigen (PSA) tests results in low cancer predictive ability and increases the number of referrals for invasive biopsy.

About NuView Life Sciences

NuView Life Sciences is a privately held company whose mission is the development and commercialization of a new generation of molecular imaging diagnostic agents and disease-specific biomarkers. We are developing a vertically integrated, radiopharmaceutical manufacturing, and distribution organization to address current supply problems in the marketplace and facilitate development of our product pipeline.

For more information, please visit http://www.nuviewinfo.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10545119.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
2. Digital Science & SciBite Join Forces to Harness Big Data for Life Sciences
3. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
4. RoviSys Partners with POMS MES to Expand Life Sciences Capabilities
5. Best Practices for Lean Six Sigma in Clinical Development and R&D, New Xtalks Life Sciences Webinar
6. A “Fail Fast” Strategy for Lead Optimization Pharmacology and Toxicology, New Xtalks Life Sciences Webinar
7. Life Sciences Technology Conference and Career Fair on March 26th in Raleigh, NC
8. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
9. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
10. Lockheed Martin to Continue Providing Life Sciences Support to NASA
11. Nasseo Wins CONNECT Life Sciences Capital Competition and Joins CONNECT Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
(Date:10/7/2017)... , Oct. 6, 2017  The 2017 Nobel ... three scientists, Jacques Dubochet, Joachim Frank ... in cryo-electron microscopy (cryo-EM) have helped ... the structural biology community. The winners worked with ... now routinely produce highly resolved, three-dimensional images of ...
(Date:10/6/2017)... ... 06, 2017 , ... On Tuesday, October 24th, ABC² (Accelerate ... first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. ... open to the public, but registration is required. , WHAT: ABC² Brain ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):